Hoping to bag the latest Medibank dividend? Read this

Find out all you need to know about the private health insurer's upcoming dividend.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medibank shares go ex-dividend tomorrow
  • This means they will no longer trade with a dividend attached
  • The dividend of 7.3 cents per share is the highest on record for the company

Time is running out to secure the Medibank Private Ltd (ASX: MPL) dividend.

Because by this time tomorrow, it will have reached its ex-dividend date, which is the time when shares trade without their dividend.

Here are some important details to keep in mind.

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.

Image source: Getty Images

Medibank dividend

Medibank offers investors an interim dividend of 7.3 cents per share. It's fully franked too, so it carries certain tax benefits.

The dividend is payable on 29 September and has a trailing dividend yield of 3.7%.

You must hold Medibank shares before the ex-dividend date to receive the dividend.

Zooming out a little, we see that 7.3 cents per share is the highest dividend the company has ever offered investors in its dividend history, stretching back to 2015.

As my Fool colleague Cathryn pointed out, this is likely due to the company seeing a 9% boost in its net profit after tax (NPAT) for FY22 and, thus, being able to distribute higher profits to investors.

Medibank share price snapshot

Shares of Medibank currently trade for $3.655 each, up 0.69% on yesterday's closing price of $3.63.

The Medibank share price is up 9.25% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down around 8% over the same period.

The company's current market capitalisation is approximately $10 billion.

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female in elegant outfit smiling and gesturing victory with hands.
Healthcare Shares

Are Telix shares a buy after flying 40% higher in March?

Telix shares are up another 5.3% on Tuesday.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Down 30% today, is it time to buy into this beaten-down biotech share?

While there's been bad news, this company has more irons in the fire.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

What's the impact of US tariffs on Aussie drugmakers CSL and Mayne Pharma?

Is the US' bark worse than its bite?

Read more »

Health professional working on his laptop.
Healthcare Shares

Mesoblast shares are back in the red on Tuesday. Here's why

Mesoblast shares slip despite another strong quarterly sales update from Ryoncil.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Earnings Results

Why are Telix shares jumping 8% today?

The radiopharmaceuticals company's shares are starting the week strongly.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Mesoblast shares: Ryoncil® underpins strong earnings growth

Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed

Telix Pharmaceuticals lifts Q1 revenue 11%, reports pipeline progress, and keeps its full-year guidance on track.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »